Open access
Open access
Powered by Google Translator Translator

#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.

30 Aug, 2022 | 12:14h | UTC

News Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology

Original Study: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER – Nature Medicine

Related:

#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.

Randomized Trial: SGLT2 Inhibitor Improves Outcomes in Patients with Heart Failure Even in the Absence of Diabetes

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.